BofA update shows where active managers are putting money
Natera, Inc. (NASDAQ:NTRA) Chief Financial Officer Michael Burkes Brophy sold 5,064 shares of common stock on July 28 and 29, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The molecular diagnostics company, currently valued at $19.2 billion, has seen its revenue grow 51.5% over the last twelve months. The sales, all under the transaction code "S", totaled $700,670.
On July 28, Brophy sold 2,019 shares at a price of $139.8083 per share. Then, on July 29, he sold 567 shares in multiple transactions ranging from $135.83 to $136.39, 1,200 shares in multiple transactions ranging from $137.00 to $137.70, and 1,278 shares in multiple transactions ranging from $138.00 to $138.16. The weighted average prices for these sales were $136.0075, $137.4177 and $138.0125, respectively.
Following these transactions, Brophy directly owns 65,430 shares of Natera common stock. Wall Street remains bullish on the company, with analysts maintaining a "Strong Buy" consensus. Track insider transactions and access comprehensive analysis with InvestingPro, which offers 10+ additional exclusive insights about Natera’s financial health and market position.
In other recent news, Natera has reported several significant developments that could interest investors. The company has seen strong performance in the first quarter of 2025, leading RBC Capital Markets to maintain an Outperform rating with a price target of $251. This comes as Natera increased its guidance due to accelerated revenue growth and effective commercial execution. Additionally, TD Cowen raised its price target for Natera to $200, noting a 13% increase in sales, with a significant rise in clinical volumes for the Signatera product.
Medicare has expanded coverage for Natera’s Signatera MRD assay, now including a broader range of cancers, which follows a pan-cancer study presented at the 2025 ASCO Annual Meeting. This expanded coverage could enhance reimbursement opportunities for the company. Furthermore, Evercore ISI initiated coverage on Natera with an Outperform rating and a price target of $170, highlighting the potential upside. Leerink Partners also reiterated its Outperform rating with a price target of $220, following recent developments in Medicare coverage for Natera’s WGS Signatera assay. These updates reflect a positive outlook from analysts and expanded opportunities for Natera in the healthcare market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.